Everything below concerns shelf life. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
Once dissolved, the peptide is considerably less stable than the solid. Aqueous solutions are usually prepared at neutral to slightly acidic pH, filtered, and divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are a common cause of avoidable loss and are best prevented by never refreezing a thawed aliquot. Adsorption to plastic and glass surfaces can lower the measured concentration of dilute solutions, particularly below roughly 0.1 mg/mL. Buffer choice, salt content, and container material all influence how much peptide remains detectable after storage.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
| Property | Value | Notes |
|---|---|---|
| Solid storage temperature | -20 °C or below | Desiccated and protected from light |
| Solution storage temperature | -80 °C as single-use aliquots | Avoid repeated freeze-thaw cycles |
| Purity assessment method | RP-HPLC, around 214 nm | Reported as main-peak area percent |
| Identity confirmation method | ESI-MS or MALDI-TOF | Measured mass compared with calculated mass |
| Common synonyms | ACTH(4-10) analog; Met-Glu-His-Phe-Pro-Gly-Pro | Also written as Semaxum in some sources |
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Fowler was initially skeptical but was ultimately convinced that Bohr was correct, and by 1915 "spectroscopists had transferred [the Pickering–Fowler series] definitively [from hydrogen] to helium." Bohr's theoretical work on the Pickering series had demonstrated the need for "a re-examination of problems that seemed already to have been solved within classical theories" and provided important confirmation for his atomic theory. In 1938, Russian physicist Pyotr Leonidovich Kapitsa discovered that helium-4 has almost no viscosity at temperatures near absolute zero, a phenomenon now called superfluidity. This phenomenon is related to Bose–Einstein condensation. In 1972, the same phenomenon was observed in helium-3, but at temperatures much closer to absolute zero, by American physicists Douglas D. Osheroff, David M. Lee, and Robert C. Richardson. The phenomenon in helium-3 is thought to be related to pairing of helium-3 fermions to make bosons, in analogy to the Cooper pairs of electrons producing superconductivity. In 1961, Vignos and Fairbank reported the existence of a different phase of solid helium-4, designated the gamma-phase. It exists for a narrow range of pressure between 1.45 K (−271.70 °C; −457.06 °F) and 1.78 K (−271.37 °C; −456.47 °F).
=== Energy conversion === Photocatalytic water splitting is an artificial photosynthesis process in which water is dissociated into hydrogen (H2) and oxygen (O2), using artificial or natural light. Methods such as photocatalytic water splitting are currently being investigated to produce hydrogen as a clean source of energy. The superior electron mobility and high surface area of graphene oxide sheets suggest it may be implemented as a catalyst that meets the requirements for this process. Specifically, graphene oxide's compositional functional groups of epoxide (-O-) and hydroxide (-OH) allow for more flexible control in the water splitting process. This flexibility can be used to tailor the band gap and band positions that are targeted in photocatalytic water splitting. Recent research experiments have demonstrated that the photocatalytic activity of graphene oxide containing a band gap within the required limits has produced effective splitting results, particularly when used with 40-50% coverage at a 2:1 hydroxide:epoxide ratio. When used in composite materials with CdS (a typical catalyst used in photocatalytic water splitting), graphene oxide nanocomposites have been shown to exhibit increased hydrogen production and quantum efficiency.
23 May – Sunak confirms that no asylum seekers will be sent to Rwanda before the general election under UK government deportation plans. Nigel Farage, founder of Reform UK, confirms he will not stand as a candidate in the upcoming general election. Police Scotland announces that it has submitted a "standard prosecution report" concerning its investigation into SNP finances to the Crown Office and Procurator Fiscal Service. First Minister of Scotland John Swinney announces he will not accept a parliamentary committee ruling to exclude Michael Matheson from Holyrood for 27 days over his £11,000 iPad charges bill, saying the decision is "prejudiced" due to the involvement of a Conservative MSP who previously made comments about Matheson. 24 May – Sir John Redwood, MP for Wokingham, announces he will not contest the next election. Former Education Secretary Michael Gove announces he will not stand for parliament again at the next election. Junior health minister Andrea Leadsom announces she will not contest the next election. Craig Mackinlay decides he will not contest the new parliamentary seat of Thanet East after what he describes as "36 hours of intense soul searching" following the announcement of the election and his feeling that the work schedule would be too much to deal with while he continues to recover from sepsis. Greg Clark, MP for Tunbridge Wells, announces he will not contest the next general election.
Sources: en.wikipedia.org
Insulin efsitora alfa, sold under the brand name Onswik, is an antidiabetic medication used for the treatment of type 2 diabetes. It is a long-acting insulin analog developed by Eli Lilly. Insulin efsitora alfa was authorized for medical use in the European Union in August 2026, and approved for medical use in the United States in September 2026.
== External links == "Do insects have blood?". Boston Globe. October 17, 2005. Archived from the original on October 2, 2022. Bolstad, Kat (May 2, 2008). "Blue Squid Blood - Murky Water". Te Papa Tongarewa Museum of New Zealand. Archived from the original on April 2, 2015.
This reaction is strongly exothermic, so the equilibrium constant decreases with temperature. However, a temperature of around 400 °C is required in order to achieve a reasonable rate of reaction with currently available catalysts. Formation of ammonia is also favoured by high pressure, as the volume decreases when the reaction takes place. The same reaction, nitrogen fixation, occurs at ambient temperatures in nature, when the catalyst is an enzyme such as nitrogenase. Much energy is needed initially to break the nitrogen–nitrogen triple bond even though the overall reaction is exothermic. Gas-phase equilibria occur during combustion and were studied as early as 1943 in connection with the development of the V2 rocket engine. The calculation of composition for a gaseous equilibrium at constant pressure is often carried out using ΔG values, rather than equilibrium constants.
==== Inflammatory bowel disease ==== Vitamin D deficiency has been linked to the severity of inflammatory bowel disease (IBD). However, whether vitamin D deficiency causes IBD or is a consequence of the disease is not clear. Supplementation leads to improvements in scores for clinical inflammatory bowel disease activity and biochemical markers, and less frequent relapse of symptoms in IBD.
Sources: en.wikipedia.org
Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.
A high main-peak percentage says little about identity, counter-ion content, or residual solvents. It also does not distinguish an isomer or a closely eluting analog. Mass confirmation and the accompanying documentation cover those gaps.
Salt form changes mass, solubility, and hygroscopicity, and acetate and trifluoroacetate salts behave differently in solution. Storage guidance still centers on -20 °C for powder and lower temperatures for solutions. The certificate should state which salt is present.
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.